Viscoli C, Paesmans M, Sanz M, Castagnola E, Klastersky J, Martino P, Glauser M
University of Genova and National Institute for Cancer Research, Genova, Italy.
Clin Infect Dis. 2001 Jun 1;32(11):1532-7. doi: 10.1086/320514. Epub 2001 Apr 30.
Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia for these groups were 20%, 26%, and 27%, respectively (P=.0001). In a multivariate model without including antifungal prophylaxis, factors associated with bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, presence of an intravenous catheter, shock, antibacterial prophylaxis, temperature, and granulocyte count at onset of fever. When antifungal prophylaxis was included, the adjustment quality of the model improved slightly (P=.05), with an odds ratio of 1.19 (95% confidence interval [CI], 0.92-1.55) for patients receiving nonabsorbable and 1.42 (95% CI, 1.07-1.88) for those who were receiving absorbable antifungal agents. Antifungal prophylaxis with absorbable agents might have an impact on the rate of documented bacteremia in febrile neutropenia. This effect should be confirmed prospectively.
已发表的数据表明,在发热性中性粒细胞减少症中,抗真菌预防与菌血症之间存在关联。在1986年至1994年期间纳入4项试验的3002例发热性中性粒细胞减少症患者中对这种关联进行了研究。总体而言,1322例患者(44%)未接受抗真菌预防;835例(28%)接受了吸收性差的抗真菌药物,845例(28%)接受了可吸收的抗真菌药物。这些组的菌血症发生率分别为20%、26%和27%(P = 0.0001)。在一个未纳入抗真菌预防的多变量模型中,与菌血症相关的因素有:年龄、住院时间、入组前中性粒细胞减少的持续时间、基础疾病、静脉导管的存在、休克、抗菌预防、体温以及发热开始时的粒细胞计数。当纳入抗真菌预防时,模型的校正质量略有改善(P = 0.05),接受不可吸收抗真菌药物的患者的比值比为1.19(95%置信区间[CI],0.92 - 1.55),接受可吸收抗真菌药物的患者的比值比为1.42(95%CI,1.07 - 1.88)。使用可吸收药物进行抗真菌预防可能会对发热性中性粒细胞减少症中记录的菌血症发生率产生影响。这种效应应通过前瞻性研究加以证实。